EngenderHealth

According to the EngenderHealth audit of June 30, 2019 (Note 3, Concentration of Credit Risk):

"...Total contributions and private grants revenue received from one donor aggregate to 29% and 71% during 2019 and 2018, respectively..."

According to the EngenderHealth audit of June 30, 2019 (Note 11, Commitments and Contingencies):

"On May 1, 2018, EngenderHealth relocated its headquarters from New York City to Washington, DC. At June 30, 2019, the remaining lease obligation on the New York City office space was $8,386,395. Using third party real estate professionals and appraisers, management estimated potential lease income of $8,166,832 through the remainder of the lease period. At June 30, 2019 and 2018, EngenderHealth estimated the liability on the exit of its rental obligation to be $854,491 and $1,057,940, respectively..."

According to the EngenderHealth audit of June 30, 2019 (Note 16, Management's Discussion of Current Economic Environment and Plan to Improve Results of Operations, re: COVID-19):

"Due to the COVID-19 pandemic, EngenderHealth is expecting a short-term reduction of revenue because some programmatic activities may be delayed while the world addresses this global health crisis. However, EngenderHealth's major donors, both governmental and private, have reached out to express their support and flexibility with their current awards. ... EngenderHealth cannot yet assess the financial impact of program changes due to the pandemic. However, management knows that the need for the work EngenderHealth performs will only be amplified during the COVID-19 response and recovery periods, and management anticipates maintaining and expanding program engagement, especially during the recovery period. With this opportunity and the current support of EngenderHealth's donors to offset short-term challenges, management maintains a strong outlook for fiscal 2020 and 2021."

[...]

"EngenderHealth has taken proactive measures to protect its staff in the US as well as overseas... Staff has pivoted quickly to working from home in the US and in some of EngenderHealth's international offices, moving additional business systems online and ensuring staff are connected by technology. Management is working with EngenderHealth's host country governments to support COVID-19 response efforts and to ensure that its support for sexual and reproductive health services continues uninterrupted...

"Management is also facilitating conversations among EngenderHealth's international non-governmental organization ('NGO') partners, both at the executive level and at the program management level. Through this coordination management is aligning EngenderHealth's policies and practices...to ensure that EngenderHealth's collective staff are safe and supported and its joint projects are protected.

"The COVID-19 pandemic is unprecedented for all of the international NGOs and the governments of the countries where EngenderHealth works. Because of the work EngenderHealth does, management has perspectives and skills that are useful and needed during this time. EngenderHealth is standing with its partners and colleagues in solidarity to ensure a productive response and a swift recovery."

According to the EngenderHealth audit of June 30, 2019 (Note 17, Subsequent Events):

"Subsequent to year end, the COVID-19 pandemic has resulted in substantial volatility in the global financial markets. As a result, EngenderHealth's investment portfolio has incurred a significant decline in its fair value since June 30, 2019. Because the value of EngenderHealth's individual investments have and will fluctuate in response to changing market conditions, the amount of losses, if any, that will be recognized in subsequent periods, cannot be determined."

According to the EngenderHealth (EH) tax filing for the fiscal year ended June 30, 2019, EH reports re: Compensation, Supplemental Information (IRS Form 990, Schedule J, Part III):

Regarding severance payments to officers, directors, trustees, key employees and highest compensated employees (Schedule J, Part I, Line 4a):

"Pursuant to the terms and conditions stipulated in Mr. Richard Killian's severance agreement, the organization paid a severance payment to Mr. Richard Killian in the amount of $50,036 in [calendar year] 2018. The payment was treated as taxable compensation to the recipient.

"Pursuant to the terms and conditions stipulated in Ms. Carmela Cordero's severance agreement, the organization paid a severance payment to Ms. Carmela Cordero in the amount of $107,105 in [calendar year] 2018. The payment was treated as taxable compensation to the recipient.

"Pursuant to the terms and conditions stipulated in Mr. Mark Barone's severance agreement, the organization paid a severance payment to Mr. Mark Barone in the amount of $87,278 in [calendar year] 2018. The payment was treated as taxable compensation to the recipient."

EH reports Richard Killian as "Project Director thru 09/19/18"; Carmela Cordero as "Sr. Clinical Advisor thru 04/30/18"; and Mark Barone as "Sr. Clinical Advisor thru 04/30/18." Their reported total compensation in calendar year 2018 is $233,763; $196,659; and $160,434, respectively (IRS Form 990, Schedule J, Part II).